|
AKI
|
Acute hyperglycemia (ABG ≥ 198 mg/dL)
|
Stress hyperglycemia (SHR ≥ 1.23)
|
|---|
|
OR (95% CI)
|
P value
|
OR (95% CI)
|
P value
|
|---|
|
Overall DM
|
1.60 (1.03–2.49)
|
0.036
|
2.43 (1.49–3.95)
|
< 0.001
|
|
History of DM
|
|
Newly diagnosed
|
1.36 (0.54–3.42)
|
0.511
|
2.17 (1.04–5.13)
|
0.039
|
|
Known before
|
1.61 (0.94–2.75)
|
0.079
|
2.73 (1.53–4.84)
|
0.001
|
|
Duration of DM
|
|
< 10 years
|
1.30 (0.70–2.39)
|
0.398
|
2.05 (1.05–4.01)
|
0.035
|
|
≥ 10 years
|
2.02 (0.98–4.15)
|
0.056
|
3.10 (1.45–6.63)
|
0.003
|
|
Prior treatment
|
|
No medication
|
1.37 (0.65–2.91)
|
0.402
|
2.76 (1.13–4.95)
|
0.032
|
|
Oral antidiabetics
|
1.80 (0.77–4.21)
|
0.173
|
2.61 (1.06–6.42)
|
0.036
|
|
Insulin use
|
1.19 (0.51–2.75)
|
0.678
|
2.56 (1.06–6.19)
|
0.037
|
- Multivariate logistic regression analysis for prognostic effect of acute or stress hyperglycemia on AKI risk in overall and subgroups of DM patients. Acute hyperglycemia was defined as ABG ≥ 198 mg/dL (11 mmol/L). Stress hyperglycemia was defined as SHR ≥ 1.23. This cut-off value of SHR was identified with maximum Youden index in all patients for AKI prediction using ROC analysis. Patients were stratified according to diabetic history, duration and prior treatment
- OR was adjusted for age, gender, MI classification (STEMI or NSTEMI), PCI treatment (with or without) and peak TnI in the multivariate model
- ABG, admission blood glucose; SHR, stress hyperglycemia ratio; DM, diabetes; AKI, acute kidney injury; OR, odds ratio; CI, confidence interval
